Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alvotech Swiss AG
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female ≥18 years old
Subjects with diagnosis of nAMD (wet), DME, RVO, DR, or myopic CNV in the study eye
Study eye considered by the Principal Investigator to be indicated for treatment with aflibercept
Subjects must sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form (ICF) before any study-specific procedures
Willing and able to comply with all study procedures and be likely to complete the study
Subjects must be able to follow the contraception requirements
You may not be if
Any concurrent ocular condition in the study eye which, in the opinion of the Principal Investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of IVT injections, or which otherwise may interfere with the injection procedure or with evaluation of safety
Current systemic infectious disease or a therapy for active infectious disease Any condition that, in the Principal Investigator's opinion, can interfere with full participation in the study, including administration of the study treatment and attending required visits; can pose a significant risk to the subject, or interfere with interpretation of study data